CHMP recommends EU approval of Roche's Ocrevus for children and adolescents with relapsing multiple sclerosis (Roche Press Release) - Sep 18, 2026 - "A final decision from the European Commission is expected in the near future....The CHMP's positive opinion is based on the Phase III OPERETTA 2 study, which showed that Ocrevus was non-inferior to fingolimod (the current standard treatment in paediatric MS) at controlling relapses, reducing the risk of relapses by 48% compared with fingolimod."
CHMP • Multiple Sclerosis
|